Hot on the heels of the AZ/Silence deal.
Roche said it has entered into an alliance with US-based biopharmaceutical company Alnylam Pharmaceuticals Inc with the Swiss pharma group obtaining a non-exclusive license to Alnylam's technology platform for developing genetic therapeutics, called RNAi.
Under the terms of the agreement, Roche will pay Alnylam 331 mln usd in upfront cash payments and equity investment, including 1.975 mln shares of Alnylam common stock at 21.50 usd per share, or just less than 5 pct of Alnylam's outstanding common stock, Roche said.
However, Roche said the alliance could be valued at over 1 bln usd 'in consideration of upfront payments, potential product milestone payments for multiple products and field expansion payments, excluding potential royalties on future sales of commercial products.'
The close of the agreement is subject to certain regulatory approvals and is expected to occur within approximately 30 days.
RNAi is a natural mechanism that the body uses to inhibit expression of certain genes, with research attempting to harness the activity of RNAi creating a direct opportunity to develop specific and potent drugs against diseases, Roche said.
Source
No comments:
Post a Comment